WO2012019423A1 - Inhibiteur d'angiogenèse, son procédé de purification et composition pharmaceutique le contenant - Google Patents

Inhibiteur d'angiogenèse, son procédé de purification et composition pharmaceutique le contenant Download PDF

Info

Publication number
WO2012019423A1
WO2012019423A1 PCT/CN2011/001000 CN2011001000W WO2012019423A1 WO 2012019423 A1 WO2012019423 A1 WO 2012019423A1 CN 2011001000 W CN2011001000 W CN 2011001000W WO 2012019423 A1 WO2012019423 A1 WO 2012019423A1
Authority
WO
WIPO (PCT)
Prior art keywords
angiopoietin
buffer
chain
injection
elution
Prior art date
Application number
PCT/CN2011/001000
Other languages
English (en)
Chinese (zh)
Inventor
李小羿
戴向荣
杨中强
张国辉
方丽
钱芳
刘娟娟
Original Assignee
兆科药业(香港)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 兆科药业(香港)有限公司 filed Critical 兆科药业(香港)有限公司
Publication of WO2012019423A1 publication Critical patent/WO2012019423A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Angiopoietin purification method thereof and pharmaceutical composition containing same
  • the present invention relates to the field of biomedicine, and in particular to an inhibitor of angiogenesis, and more particularly, to an angiopoietin, a method for purifying the same, and a pharmaceutical composition containing the same. Background technique
  • Tumor angiogenesis (ang iogenes i s) refers to the complex biological process by which vascular endothelial cells differentiate and migrate from existing vascular systems to form new microvessels.
  • Adult endovascular cells are basically at rest, and new blood vessels are formed under physiological stimulation such as wound healing, tissue repair, female fertility and menstrual period, fetal development, which is physiological angiogenesis.
  • angiogenesis is under the strict control and coordination of stimulating factors and inhibitors.
  • the proliferating endothelial cells quickly return to a normal resting state.
  • angiogenesis-dependent diseases such as rheumatoid arthritis, diabetic or macular degeneration retinopathy, infantile hemangiomas, and malignant tumors.
  • angiogenesis-dependent diseases such as rheumatoid arthritis, diabetic or macular degeneration retinopathy, infantile hemangiomas, and malignant tumors.
  • Folkman clarified the importance of tumor angiogenesis in tumor development, metastasis and spread, and suggested that inhibitors of angiogenesis may become a new and valuable treatment for cancer.
  • disrupting angiogenesis plays an important role in cancer research. Endogenous and exogenous tumor angiogenesis inhibitors provide a new clinical drug orientation for the treatment of such diseases.
  • Snake venom is a venom secreted from the venom gland of snakes. It mainly contains proteins, peptides and some enzymes, and has a wide range of biological activities. At present, many components of snake venom have been studied intensively, and they have a good effect on antithrombotic, hemostasis, analgesic and anti-tumor. Since the separation and purification of snake venom in 1965, it has been possible to find specific anti-tumor components that have entered cell and molecular levels, many of which have been found to have varying degrees of in vivo or in vitro anticancer activity. . Persistent angiogenesis is a feature of tumor growth.
  • Angiogenesis is not only necessary for tumor growth, but the contact of tumor cells with the neovascular system is also responsible for distant metastasis. In recent years, the treatment of tumors has mainly relied on the development of new drugs and gene therapy. Such as the Chinese patent entitled “angiogenesis inhibitory peptide and its preparation method and application”
  • 2QQ61Q (929S. 2 discloses a polypeptide obtained by modifying the amino acids 6 to 49 of endostatin, which has stronger in vivo antitumor activity and tumor targeting than endostatin.
  • the E. coli expression system used in the invention has a high expression level, the obtained inclusion body protein is difficult to dissolve and difficult to reconstitute, which is easy to cause inconvenience; even if the protein is refolded and soluble, the process will lose a large amount of protein, resulting in low utilization rate.
  • endostatin has a short half-life in vivo, and the preparation process of the angiogenesis-inhibiting polypeptide is complicated and relatively high in cost, which is not conducive to large-scale production. Therefore, some malignant degrees are high, the surgical cure rate is low, and It is very important to actively seek new safe and effective anti-tumor drugs for tumors that are not sensitive to radiotherapy and chemotherapy.
  • the present invention aims to solve at least one of the technical problems existing in the prior art. Accordingly, it is an object of the present invention to provide an angiopoietin which achieves an antitumor effect by inhibiting tumor angiogenesis.
  • Another object of the present invention is to provide a method for purifying the angiopoietin. It is still another object of the present invention to provide a pharmaceutical composition for inhibiting tumor angiogenesis to achieve an antitumor effect.
  • an angiopoietin having an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, having non-reducing SDS-PAGE (non-reducing polyacrylamide gelation)
  • SEQ ID NO. 1 having non-reducing SDS-PAGE (non-reducing polyacrylamide gelation)
  • SDS-PAGE non-reducing polyacrylamide gelation
  • the molecular weight between 25,000 ⁇ 35 t) D0 Daltons determined by gel electrophoresis has anti-angiogenic activity.
  • the angiopoietin according to the present invention can effectively inhibit unwanted angiogenesis, particularly angiogenesis associated with tumor growth, and is more effective in antitumor and tumor metastasis.
  • the angiopoietin is reduced by SDS-PAGE (also The original polyacrylamide gel electrophoresis method showed two bands, called CX chain and ⁇ chain, respectively, and the molecular weights were 12000 ⁇ 22000 Daltons and 9000 ⁇ 199000 Daltons respectively.
  • the amino acid sequence of the ⁇ chain was as follows. The amino acid sequence of the ⁇ chain is shown in SEQ ID NO.
  • the amino acid sequence is substituted, deleted, or added by one or several amino acid residues and has a protein derived from angiogenic activity.
  • the angiopoietin of the present invention can improve the amino acid sequence under the condition that the angiogenesis activity is not affected, for example, mutating, deleting or adding one or several amino acids to one or several amino acids respectively does not affect the activity of the protein. Even some amino acid changes may optimize the properties of angiogenesis inhibition, which can be achieved by standard procedures by those skilled in the art.
  • the angiopoietin is produced by two-dimensional electrophoresis to produce three isomers corresponding to the ⁇ chain and the ⁇ chain, respectively.
  • the hematopoietic tuberogen can obtain six bands, wherein the o chain and the ⁇ chain each have three bands.
  • the identification of the six bands by mass spectrometry indicates that they are isoforms of the two subunits ⁇ and ⁇ , respectively, that is, the protein will produce isomers due to its structural specificity under isoelectric aggregation conditions. As a result, six bands appear in the two-dimensional electrophoresis, and there is no single isoelectric point.
  • the angiopoietin specifically binds to the secreted monoclonal antibody by hybridoma cell line 1D91D9, accession number CCTCC C201036, and the main resistance of the monoclonal antibody secreted by the hybridoma cell line is Angiopoietin specifically binds.
  • the hybridoma was deposited on April 14, 2010 at the China Center for Type Culture Collection of Wushan University, Wuhan, Wuchang, Hubei province, under the name Hybridoma Cell Line 1D91D9, and the accession number is CCTCC C201036.
  • the angiopoietin is capable of inhibiting tumor growth, wherein the tumor is selected from the group consisting of human melanoma, He la cells, and K562 cells.
  • the snake venoms related to anti-tumor effects reported in domestic and foreign literatures are the most cobra and python, and the golden snake, the scorpion snake, and the rattlesnake venom.
  • the source of snake venom is mainly to take snakes or snakes to extract snake venom.
  • snake venoms are different in species, different in origin, and even snakes of the same species.
  • the composition of the venom is different during the collection period. Therefore, the purification process of snake venom is difficult to fix.
  • the barramundi is the only one of the genus Aphididae, also known as the snake, which is widely distributed in China. Among them, the Wuyishan Mountain Area and the Weinan Mountain Area have the most storage. Living in mountainous or hilly woods and lush places, the vertical distribution range is 100 - 1350 meters above sea level.
  • the Agkistrodon acutus venom used in the present invention is purchased from Huizhou Institute of Venom and Venom in Huangshan City.
  • the present invention adopts the principle of modern immunology, combines antigen-antibody specific reaction and affinity chromatography technology, and separates and purifies angiopoietin from the crude venom of sharp python. .
  • the method first extracts a crude solution of angiopoietin from the crude venom of Agkistrodon acutus, and then obtains the crude product of angiogenin by cation exchange chromatography and gel chromatography respectively;
  • the primary purified substance is an antigen, and a specific monoclonal antibody specific thereto is prepared; and then coupled to an appropriate affinity chromatography carrier to prepare an antibody affinity chromatography column; finally, the antibody affinity chromatography obtained by coupling is used.
  • the column can be subjected to immunoaffinity chromatography on a crude solution of angiopoietin having an inhibitory activity on angiogenesis to prepare a high-purity angiopoietin.
  • the method for purifying the angiopoietin of the present invention comprises the following steps:
  • the buffer in the step (a) is a 0.01 to 0.1 lmol/L Tris-HCl buffer solution having a pH of 7.0 to 9.0.
  • the Agkistrodon acutus was centrifuged twice for centrifugation at a rate of 4000 r/min and centrifuged for 15 min each time.
  • Step (b) Linear gradient elution with 0.01-0.05 mol/L Tris-HCl buffer and 0.05-0.6 mol/L NaCl solution at pH 6.0-9.0 as eluent.
  • the affinity chromatography column carrier of the step (c) is any one of a 4B agarose gel, a diethylaminodextran gel, and a carboxymethyldextran gel.
  • the elution buffer of the step (d) is pH 2. 0 ⁇ 4. 0, 0. 01 0. 03 mol / L G ly-HCl buffer, the elution time is 480 min, and the elution flow rate is 5 ml /mi.n.
  • the present invention also provides a pharmaceutical composition for inhibiting tumor angiogenesis to achieve an antitumor effect.
  • the pharmaceutical composition contains angiopoietin and contains a pharmaceutically acceptable carrier.
  • the present invention also provides an injection comprising angiostatin and a pharmaceutically acceptable excipient, a stabilizer.
  • At least 1 mg of the angiogenin raw material is contained per ml of the injection, and then a pharmaceutically acceptable excipient, a stabilizer is directly or indirectly added by conventional processing to prepare an injection.
  • the injection contains at least 1 mg of angiopoietin, 32 - 48 mg of dextran, and 1.6 to 2.4 mg of trehalose per ml.
  • the angiopoietin of the present invention has the following advantages: First, the specificity is strong. Cancer treatment currently uses surgery, radiotherapy, chemotherapy, biological therapy and combination therapy. The common features of various anticancer drugs that can be used for chemotherapy are the inhibition of the proliferation of all rapidly dividing cells, but the lack of anti-cancer cell proliferation. The specificity, while resisting the proliferation of cancer cells, has great toxic and side effects on the rapidly dividing cells in the gastrointestinal and other tissues and organs of the bone marrow.
  • the anti-angiogenin of the invention has strong specificity, and can effectively inhibit tumor growth and metastasis by inhibiting unwanted angiogenesis, particularly angiogenesis related to tumor growth; secondly, high utilization rate, relatively precise preparation process Simple.
  • the preparation process of the angiopoietin of the invention is simple, can overcome the shortcomings of short half-life of endogenous angiogenesis inhibitors, and avoids the cause of recombination or transgenesis.
  • the problems of low transfection rate, low protein utilization rate and high cost, and high reproducibility and low cost are beneficial to industrial production.
  • snake venom has anti-thrombotic, hemostasis, analgesic and its anti-tumor effect. It has received wide attention worldwide. China's snake venom resources are abundant and have broad research and application prospects.
  • the hybridoma cell line established according to the present invention was deposited on April 14, 2010 at the China Center for Type Culture Collection (CCTCC) of Wuhan University, Wuchang, Wuhan, Hubei province, under the accession number C201036, and the classification is Hybrid. Tumor cell line 1D91D9.
  • Figure 1 is a flow chart showing the preparation process of angiopoietin according to the present invention
  • Figure 4 is a diagram showing the ultraviolet absorption (280 nm) of gel S-100 column chromatography in the preparation process of angiopoietin according to an embodiment of the present invention
  • Figure 5 is a chromatographic ultraviolet absorption (280 nm) map of an affinity chromatography column in the preparation of angiopoietin according to an embodiment of the present invention
  • Figure 6 is a non-reducing SDS-PAGE electropherogram of angiopoietin according to an embodiment of the present invention.
  • Figure 7 is a two-dimensional electropherogram of angiopoietin according to one embodiment of the present invention (28-1, 28-2, 28-3, 28-4, 28-5 represent five band spots, respectively);
  • Figure 8 is a graph showing the inhibitory effect of angiopoietin on chicken embryo angiogenesis in a chicken chorioallantoic membrane model in accordance with one embodiment of the present invention
  • Figure 9 is a graph showing changes in body weight of mice after 4 weeks of administration of an inhibitor of angiogenin against transgenic mouse colon cancer in accordance with one embodiment of the present invention.
  • Figure 10 is a graph showing the effect of angiopoietin on tumor mass in an in vivo pharmacodynamic test against angiogenic colon cancer in accordance with one embodiment of the present invention
  • Figure 11 is a graph showing the effect of angiopoietin on the number of tumors of different sizes in an in vivo pharmacodynamic test against angiogenic murine colon cancer in accordance with one embodiment of the present invention.
  • the invention adopts the principle of modern immunology, combines antigen-antibody specific reaction and affinity chromatography technology to separate and purify angiopoietin from the crude venom of Agkistrodon acutus.
  • Figure 1 is a flow chart showing the preparation process of angiopoietin according to the present invention. As shown in Figure 1: First, the crude venom of Agkistrodon acutus is dissolved in the buffer for a certain period of time, and then the supernatant is centrifuged to obtain a solution of Agkistrodon acutus venom; the resulting snake venom solution is anion exchange chromatography to inhibit angiogenesis.
  • a crude solution of the prime followed by taking an appropriate amount of the crude solution through cation exchange chromatography and gel chromatography to prepare an initial product of angiopoietin; and then, using the pure product as an antigen, preparing a specific single for the same
  • the antibody is cloned; then, coupled with a suitable affinity chromatography carrier to prepare an antibody affinity chromatography column; finally, the previously prepared antibody affinity chromatography column is used to inhibit the angiogenic activity.
  • the crude angiogenin solution is subjected to immunoaffinity chromatography to prepare a high-purity angiopoietin.
  • the obtained supernatant was applied to an equilibrated anion exchange chromatography DEAE column at a flow rate of 3.0 ml/min. After loading, it was first eluted with 0.02 mol/L pH 8.5 Tris-HCl buffer. The heterogeneous protein adsorbed by the medium was eluted for 360 min, and the elution flow rate was 3 ml/min. Then, 0.5 mol/L NaCl was added to the 0.02 mol/L pH 6.5 Tris-HCl buffer.
  • the collected crude anti-angiogenin solution is ultrafiltered with a membrane having a molecular weight cut off of 10,000, concentrated to a volume of 30-80 ml, and transferred to a cooked dialysis bag, and placed in a refrigerator at 4 ° C. Internal dialysis for 6 ⁇ 12h. Then, the sample obtained after dialysis was applied to an equilibrated cation exchange chromatography CM (carboxylated cellulose) column at a flow rate of 3.0 ml/min, and then loaded with 0.02 mol/L Tris-pH 6.5.
  • CM carboxylated cellulose
  • the HCl buffer eluted the heteroprotein that could not be adsorbed by the chromatographic medium, the elution time was 360 min, the elution flow rate was 3 ml/min, and then 0.5 mol/L was added to the 0.02 mol/L Tris-HCl buffer at pH 8.5.
  • the gradient elution (0-100%) was carried out with NaCl, the elution time was 1440 min, and the elution flow rate was 5 ml/min.
  • components having an activity of inhibiting angiogenesis are collected.
  • the protein detection was carried out by using the purification system AKTA prime plus with a UV detector at 280 nm.
  • the UV absorption spectrum is shown in Figure 3. The collection was collected by the system's partial collector, and the collection was set to 4 min/tube. The first product of pheromone.
  • the collected anti-angiogenin initial solution is ultrafiltered with a filter having a molecular weight cut off of 10,000, concentrated to a volume of 30-80 ml, and then subjected to a millipore ultra series centrifugal ultrafiltration tube at 4 ° C for low temperature. Concentrate by centrifugation ultrafiltration and concentrate the volume to 5 ⁇ 15ml. Then, the sample obtained after concentration was applied to an equilibrated gel chromatography S-100 column at a flow rate of 1.0 ml/min, and 0.15 mol/L was added to a 0.02 mol/L pH 7.6 Tris-HCl buffer.
  • the NaCl was eluted with an elution time of 960 min and an elution flow rate of 0.3 ml/min. Finally, components having inhibitory angiogenic activity are collected.
  • the detection method is the same as above.
  • the protein detection is detected by the purification system AKTA prime plus with UV detector at .28Gnm.
  • the UV absorption spectrum is shown in Figure 4.
  • the collection is collected by the system with the fraction collector, and the collection is set to lOmin/tube.
  • the obtained sample is an initial pure product of angiopoietin. 3.
  • CTCC accession number is C201036, and the classification is named hybridoma cell line 1D91D9.
  • the purified anti-angiogen monoclonal antibody was dialyzed against 0. lmol/L sodium citrate buffer at 4 ° C overnight, and then added with 10 ml of CNBr-Sepharose 4B, cyanogen bromide-conjugated agarose.
  • Gel 4B to 10 ml of antibody solution, was placed on a shaker or shaker and gently shaken overnight at 4 °C. Then, 1 ml of a 2 mol/L ethanolamine solution was added to block the residual active group of CNBr-Sepharose 4B, and shaking was continued for 1 hour at 4 °C.
  • the antibody-conjugated Sepharose 4B (Sepharose 4B) column was loaded onto an appropriate column.
  • the column was washed with 0. lmol/L of sodium citrate buffer, followed by elution with twice column volume of 0.1 mol/L, pH 6.5, NaCl sodium citrate buffer containing 1 mol/L. Finally, elute with twice the column volume of PBS (phosphate buffer).
  • PBS phosphate buffer
  • the crude solution of the angiopoietin obtained by the anion exchange chromatography in step 2 (1) is subjected to ultrafiltration and concentration, and then the affinity buffer is used to equilibrate the buffer, specifically 0.02 mol / L of Tr i s-HCl. I. dialysis, pH 7.8, containing 0.05 mol / L of NaCl.
  • the antibody is then affinity-column and equilibrated with the affinity chromatography equilibration buffer described above until the eluent elution profile is shown as baseline after UV detection.
  • the activity peak was collected by elution with Gly-HCl buffer at pH 4.0, 0.02 mol/ml, glycine-hydrochloric acid buffer as an affinity chromatography eluate.
  • the detection method is the same as above.
  • the protein detection is detected by the purification system AKTA pr ime p lus with UV detector at 280mn.
  • the UV absorption spectrum is shown in Figure 5.
  • the collection is collected by the system's branch collector.
  • the collection is set to 1 ⁇ 2in/ Tube, the obtained sample is a high-purity angiopoietin.
  • the above preparation method was repeated 10 times, numbered 1-10 groups.
  • Purity identification a group of high-purity angiopoietin group 3 samples obtained in Example 1 were randomly selected for non-reducing SDS-PAGE electrophoresis (polyacrylamide gel electrophoresis), as shown in Fig. 6, showing a band , the molecular weight is 30,000 35,000 Daltons.
  • Structural identification The third group of samples extracted above were subjected to two-dimensional electrophoresis, ie, isoelectric aggregation electrophoresis and reduction SDS-PAGE electrophoresis. As shown in FIG. 7, the angiopoietin can obtain six bands after two-dimensional electrophoresis. Wherein the alpha chain and the beta chain each have three bands. The identification of six bands by mass spectrometry showed that they are isoforms of two subunits, that is, the isoforms of the protein due to its structural specificity under isoelectric aggregation conditions, resulting in Six strips appear in two-dimensional electrophoresis and do not have a single isoelectric point.
  • Test criteria for angiopoietin hemorrhagic toxicity The three groups (Group 1, Group 4, Group 9) obtained in Example 1 were randomly selected to obtain high-purity angiopoietin, respectively, and sodium chloride injection was used respectively. Prepare a solution containing 20 units per ml; then select 15 mice with a body weight of 18-22 g, 5 samples per group, subcutaneously inject 0.2 ml of the solution; then, sacrifice the animals 24 hours after the injection. , peeling observation, no bleeding on the back of the mouse.
  • Anti-angiogenin neurotoxicity test criteria Take the appropriate amount of high-purity angiopoietin in group 1, group 4, and group 9 above, and prepare 20 units per milliliter with sodium chloride injection. Solution; then select 9 pigeons with a body weight of 300 ⁇ 500g, 3 samples per group; the dose used is 0.5 ml per kg injection, intravenously, for 24 hours, the animals shall not have convulsions or death. For example, in each of the three groups, one of the three patients had convulsions or death, and another five retests were performed, and no death occurred.
  • the endotoxin content per unit sample is not higher than 20EU.
  • the specific detection methods are as follows:
  • the color of the substrate is added to the above reaction wells to temporarily prepare 0PD (o-phenylenediamine) substrate reaction solution 0.1 ml, reaction at 37 ° C for 10 ⁇ 30min, plus 2mol / L 0. 05ml H 2 S0 4 to terminate the reaction.
  • 0PD o-phenylenediamine
  • the angiostatin prepared according to the first embodiment of the present invention and qualified by the test is used as a raw material medicine according to the formula, and the auxiliary materials such as dextran are accurately weighed in the liquid-dispensing container, and the injection is added.
  • the mixture was sufficiently dissolved or diluted with water to make the concentration of dextran 1%, and the mixture was stirred and mixed to obtain a preparation intermediate.
  • sterile filtration in which the integrity of the sterilization filtration system should be tested before and after filtration.
  • the filtered intermediates are loaded into the vials according to the loading, and at least 4 loadings should be checked during the dispensing process to ensure that the amount of the drug loaded in each bottle is accurate.
  • the vials filled with the drug are lyophilized, vacuumed, and slowly warmed to 35 to 40 ° C under vacuum, and then kept down to room temperature for a certain period of time and taken out, and the finished product is pressed and rolled.
  • the injection angiopoietin prepared in Example 4 was used in the following experiment.
  • VEGF vascular endothelial growth factor
  • the drug and its monoclonal antibody (excess) are fully combined and administered, the drug has no inhibition on the growth of chicken embryo blood vessels, and is as strong as the blood vessel growth in the positive control group, indicating that the blood vessel growth is inhibited by the action of the drug. .
  • the drug and its monoclonal antibody (excess) were fully combined and administered, the drug did not substantially inhibit the growth of chicken embryo blood vessels, and the blood growth of the positive control group was as strong.
  • HUEVCs human umbilical vein endothelial cells
  • FBS fetal bovine serum
  • VEGF vascular endothelial growth factor
  • angiopoietin significantly reduced the growth factor-induced HUVECs cell invasion through the matrigel surface, and this decrease was dose-dependent with the dose administered.
  • angiopoietin is an integrin receptor inhibitor
  • an adhesion test of HUEVCs cells was designed, using a known integrin inhibitor as a control group, and the results showed that the sample was integrin avb 3/ Avb5 mediated adhesion did not significantly affect.
  • angiopoietin has a direct and significant inhibitory effect on endothelial cell differentiation, migration and invasion, but there is no proliferation and adhesion to endothelial cells. Significant impact. This suggests that the angiopoietin mechanism is not significantly associated with growth factor (VEGF and FGF2) or tyrosine protease receptor-related signaling pathways.
  • MTT (4, 5-dimercaptothiazole_2)-2, 5-diphenyltetrazolium bromide; trade name: thiazole blue) method for detection of melanoma, Hela cells and K562 Inhibition.
  • results of in vitro inhibition of angiopoietin on melanoma, Hela cells and K562 cells indicate: relative avastin (Avastin, also known as bevacizumab, human vascular endothelial growth factor VEGF monoclonal antibody) and cisplatin, angiogenesis
  • Avastin also known as bevacizumab, human vascular endothelial growth factor VEGF monoclonal antibody
  • cisplatin angiogenesis
  • the pheromone has a significant inhibitory effect on melanoma A375 cells, and also has a significant inhibitory effect on Hela cells, and the inhibitory effect on K562 cells is not obvious.
  • the mode of administration was intraperitoneal injection twice a week for 4 weeks.
  • the experimental design was control group (normal saline, 3 rats), test group 1 (low dose group, 10 yg, 3 rats), test group 1 (high dose group, 45yg, 3 rats), results examination method ⁇ microscopy
  • the main parameters of the method, detection and determination include: mouse body weight change, number of tumor nodules, effective solid tumor size.
  • the maximum tolerated or median lethal dose was initially estimated by observing the acute toxicity of a single intravenous injection of angiopoietin into Kunming mice.
  • mice Eight Kunming mice were used for the experiment, and four dose groups were set up, two in each group, half male and half female.
  • Intravenous administration the administration volume is 0.25mL/10g, and the administration dose is 14.5, 10.88, 8.16, 6. 12 mg/kg body weight, continuous observation for 4 days after drug administration.
  • the maximum tolerated dose (MTD) of Kunming mice administered by single intravenous injection of angiopoietin for injection was greater than or equal to 14. 5 mg/kg body weight.
  • angiopoietin for injection has different degrees of inhibition on melanoma, Hela cells and K562, and can effectively inhibit colon cancer growth in transgenic mice implanted into colon cancer model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne un inhibiteur d'angiogenèse, ayant une séquence d'acides amines choisie parmi SEQ ID N°: 1 ou SEQ ID N°: 2, et un poids moléculaire, déterminé par SDS-PAGE non réductrice, de 25000-35000 daltons. Cette invention concerne, en outre, un procédé de purification dudit inhibiteur d'angiogenèse par chromatographie d'échange d'anions et chromatographie d'immunoaffinité, et une composition pharmaceutique et un produit à injecter le contenant.
PCT/CN2011/001000 2010-08-13 2011-06-16 Inhibiteur d'angiogenèse, son procédé de purification et composition pharmaceutique le contenant WO2012019423A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010252717.7 2010-08-13
CN201010252717.7A CN102372770B (zh) 2010-08-13 2010-08-13 一种抑血管生成素、纯化方法及含有它们的药物组合物

Publications (1)

Publication Number Publication Date
WO2012019423A1 true WO2012019423A1 (fr) 2012-02-16

Family

ID=45567311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001000 WO2012019423A1 (fr) 2010-08-13 2011-06-16 Inhibiteur d'angiogenèse, son procédé de purification et composition pharmaceutique le contenant

Country Status (2)

Country Link
CN (1) CN102372770B (fr)
WO (1) WO2012019423A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005241A1 (fr) * 2012-07-02 2014-01-09 兆科药业(香港)有限公司 Utilisation pharmaceutique d'angiostatine
CN102847137A (zh) * 2012-07-02 2013-01-02 兆科药业(香港)有限公司 抑血管生成素的药物用途
CN104387499B (zh) * 2014-08-15 2017-02-08 济南盛岳林生物工程有限公司 一种利用免疫亲和技术提纯硫酸软骨素的方法
CN113185595B (zh) * 2020-12-11 2023-05-09 兆科（广州）眼科药物有限公司 一种具有抑制新生血管生长及抑制炎症反应活性的蛋白质及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1733913A (zh) * 2004-08-11 2006-02-15 北京赛生药业有限公司 高纯度蛇毒激肽原酶的制备方法及其药物制剂
CN1737133A (zh) * 2004-08-16 2006-02-22 北京赛生药业有限公司 高纯度蛇毒纤溶酶的制备方法及其药物制剂
CN101358184A (zh) * 2008-09-27 2009-02-04 康辰医药股份有限公司 尖吻蝮蛇蛇毒血凝酶

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159438C (zh) * 2001-04-29 2004-07-28 中国科学院昆明动物研究所 一种尖吻蝮蛇毒凝血酶及其生产方法
CN101190943B (zh) * 2006-11-30 2010-06-09 首都医科大学 江浙腹蛇蛇毒双链肽、其制备方法及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1733913A (zh) * 2004-08-11 2006-02-15 北京赛生药业有限公司 高纯度蛇毒激肽原酶的制备方法及其药物制剂
CN1737133A (zh) * 2004-08-16 2006-02-22 北京赛生药业有限公司 高纯度蛇毒纤溶酶的制备方法及其药物制剂
CN101358184A (zh) * 2008-09-27 2009-02-04 康辰医药股份有限公司 尖吻蝮蛇蛇毒血凝酶

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 13 May 2002 (2002-05-13), "C-type lectin [Deinagkistrodon acutus]", Database accession no. AAM22788.1 *
HIROSHI MIZUNO ET AL.: "Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X", PNAS, vol. 98, no. 13, 19 June 2001 (2001-06-19), pages 7230 - 7234, XP055006613, DOI: doi:10.1073/pnas.131179698 *

Also Published As

Publication number Publication date
CN102372770A (zh) 2012-03-14
CN102372770B (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
US20110015130A1 (en) Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof
RO119721B1 (ro) Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
JP2003159083A (ja) 新規な神経栄養因子
CA1341182C (fr) Inhibiteurs de croissance tumorale derives de tissus, methode de preparation et utilisation
AU2017238817B2 (en) Conjugate vaccine targeting a disease-causing biological protein
EP0622456A1 (fr) Vecteurs procaryotiques et eucaryotiques produisant des polypeptides contenant des épitopes de PDGF-B
AU2015305299B2 (en) Disintegrin variants and pharmaceutical uses thereof
WO2012019423A1 (fr) Inhibiteur d'angiogenèse, son procédé de purification et composition pharmaceutique le contenant
US20050042201A1 (en) Histidine-rich glycoprotein
JP2007525972A (ja) エンドスタチンのｎ末端からの抗血管新生性ペプチド
WO2020238924A1 (fr) Médicament possédant une activité anti-angiogenèse et son procédé de préparation
JP2527896B2 (ja) ヒト骨由来インスリン様成長因子結合タンパク
US5175255A (en) Methods for purification of platelet-derived growth factor
JPH03155787A (ja) Ｅｂｚｄ蛋白質発現系
WO2023060483A1 (fr) Immunoconjugué polypeptide-rbd et son utilisation
WO1992007938A1 (fr) Inhibiteurs de croissance cellulaire
CN114149501B (zh) 抗c5抗体及其应用
Wei et al. Soluble multimer of recombinant endostatin expressed in E. coli has anti-angiogenesis activity
JP4256497B2 (ja) 血管炎治療剤
CA2056981A1 (fr) Inhibiteurs de croissance de tumeurs derives de tissus, methode de preparation et utilisations
DK176220B1 (da) Monoklonalt antistof, som binder human vævsfaktor-protein, samt dets anvendelse
CN114560947A (zh) 一种抑制血管生成的融合蛋白
JPH07224100A (ja) 新規トロンボモジュリン類
JPH07135994A (ja) 抗体、ポリペプチド、その製造法および用途
AU2002304352A1 (en) Histidine-rich glycoprotein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815982

Country of ref document: EP

Kind code of ref document: A1